"Settling the UGDP controversy"?
D000284:Administration, Oral / Q000009:adverse effects; D000367:Age Factors; D000368:Aged; D001699:Biometry; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000401:mortality*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012737:Sex Factors; D014044:Tolbutamide / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D010919:Placebos; D014044:Tolbutamide